An Introduction to Leukaemia
Treating leukaemia holds numerous challenges, including the need for less toxic and more cost-effective treatments. Important additions to the landscape include targeted treatments such as FLT3 inhibitors, BCL-2 inhibitors and immune therapies such as monoclonal antibodies, antibody-drug conjugates and chimeric antigen receptor (CAR) T-cell therapies have been important additions to improve patient outcomes.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Courtney DiNardo, EHA 2020: Venetoclax plus Azacitadine in AML and the VIALE-A Study
Dr Courtney DiNardo (The University of Texas MD Anderson Cancer Center, Houston, United States) joins touchONCOLOGY to discuss the key findings from the VIALE-A study and the safety and efficacy of venetoclax plus azacitadine in patients with acute myeloid leukaemia and (NCT02203773 and NCT02287233.) Questions 1. What are the limitations of current therapeutic options for […]
Mikkael Sekeres, ASCO20: New combination therapy in patients with MDS/CMML or LB AML
It was a pleasure to speak to Mikkael Sekeres to discuss the presentation of the phase II study of pevonedistat + azacitidine versus azacitidine in patients with higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia, or low-blast acute myelogenous leukemia (Clinicaltrials.gov identifier: NCT02610777). Questions 1. What are the limitations of hypomethylating agents such as, 5-azacitidine in the treatment […]
Othman Al Sawaf, ASCO20: Results of the Phase III CLL14 Trial for Chronic Lymphocytic Leukaemia
We were delighted to speak to Othman Al-Sawaf to discuss the data presented at ASCO20 Virtual Scientific Programme on the phase III CLL14 trial, which found that the BCL2 inhibitor venetoclax plus the monoclonal antibody obinutuzumab prolonged progression-free survival vs obinutuzumab and chlorambucil in patients with previously untreated chronic lymphocytic leukemia and coexisting conditions. Questions […]
Jorge E Cortes, ASCO20: Interim Analysis of the Phase II OPTIC Trial of Ponatinib in CP-CML
Jorge E Cortes, MD Anderson Cancer Center, discusses the interim analysis of the Phase II OPTIC trial presented at the ASCO20 virtual congress. The trial evaluats response-based dosing regimens of ponatinib with the aim of optimising its efficacy and safety in patients with chronic-phase chronic myeloid leukemia who are resistant or intolerant to prior tyrosine […]
Jorge E Cortes, ASCO20: 5-Year Analysis of the Phase II PACE Trial of Ponatinib in Ph+ leukemia
Jorge E Cortes, MD Anderson Cancer Center, discusses the 5-year analysis presented at ASCO20 of arterial occlusive events in the ponatinib phase II PACE trial (NCT01207440) in patients with Ph+ leukemia. Click here to view Jorge Cortes discussing the OPTIC trial. Questions 1. How has ponatinib fitted into the treatment paradigm for haematological malignancies? (0:06) […]
Brian Jonas, ASCO20: Venetoclax combination treatment in older patients with acute myeloid leukemia
Professor Brian Jonas, UC Davis Comprehensive Cancer Center, discusses the abstract presented at the ASCO20 Virtual Meeting. Abstract #EP535: Timing of response to venetoclax combination treatment in older patients with acute myeloid leukemia. Questions 1. What is the rationale for the use of venetoclax in combination with hypomethylating agents in older patients with newly diagnosed acute […]
Role of New Immunophenotypic Markers on Prognostic and Overall Survival of Acute Lymphoblastic Leukaemia – A Systematic Review and Meta-analysis
European Oncology & Haematology. 2019;15(2):113–20
Acute lymphoblastic leukaemia (ALL) is a group of malignant haematological disorders characterised by accumulation of lymphoid cell precursors that replace normal bone marrow elements and inhibit the production of functional blood cells.1 ALL occurs in both children and adults, and more than one-half (56%) of those diagnosed are <20 years old, with chemotherapy required as standard […]
Massimo Breccia, ASH 2019: Discontinuing Tyrosine-kinase Inhibitors in patients with Chronic Myeloid Leukemia
At the 61st ASH Annual Meeting & Exposition, Massimo Breccia, Sapienza University of Rome, discusses discontinuing tyrosine-kinase inhibitors (TKIs) in patients with chronic myeloid leukemia. Questions 1. What is the rationale for discontinuing tyrosine-kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML)? (0:05) 2. Following discontinuation of TKIs in patients with CML, when are […]
Naval Daver, ASH 2019: Venetoclax in Combination with Idasanutlin in Relapsed or Refractory AML
At the 61st ASH Annual Meeting & Exposition, Naval Daver, MD Anderson Cancer Center, discusses his presentation: Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy. Questions 1. What are the current therapeutic […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!